10-K: Ludwig Enterprises Faces Going Concern Amidst Diagnostic Pivot

Ludwig Enterprises, an early-stage genomic diagnostics company, reported significant losses and a going concern warning in its 2025 annual report, despite advancing its Revealia Breast test towards a Q2 2026 trial launch.

Summary

• Ludwig Enterprises is an early-stage genomic technology company focused on developing mRNA-based screening tests for inflammation-related chronic diseases, including cancers.
• The company's first product candidate, the Revealia Breast test, is a non-invasive cheek swab assay for breast cancer detection, with a trial launch anticipated in the second quarter of 2026.
• Preliminary clinical validation for the Revealia Breast test, based on 249 breast cancer samples, showed 92% sensitivity, 54% specificity, 86% negative predictive value, and an area under the curve (AUC) of 76%.
• The company reported a net loss of $2,236,433 for the year ended December 31, 2025, and an accumulated deficit of $9,495,799.
• Independent auditors raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Commercialization of products is dependent on securing additional funding for clinical validation studies, laboratory infrastructure, and distribution capabilities.
• Proposed corporate actions, approved by the Board and majority shareholders, include a reverse stock split (1-for-50 to 1-for-250) and a name change to Revealia Diagnostics, Inc.
• Management changes in 2025 included the resignation of the CEO, appointment of an Interim CEO, and the addition of new independent directors.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, early-stage investment. While the technology shows promise and addresses a significant market, the severe financial distress, going concern warning, and lack of revenue indicate substantial operational and financial challenges that outweigh the positive product development news.

Positives

• Advanced its first product candidate, the Revealia Breast test, towards an anticipated trial launch in Q2 2026.
• Preliminary clinical validation results for the Revealia Breast test show high sensitivity (92%) and negative predictive value (86%), which compare favorably to published benchmarks for mammography.
• Proprietary mRNA-based technology offers a non-invasive, patient-friendly cheek swab collection method, differentiating it from many existing diagnostic approaches.
• Holds two patent families covering diagnostic tests for multiple cancers (breast, bladder, colon, ovarian) with filings in several key global jurisdictions.
• Targets a significant market opportunity in cancer diagnostics, with the U.S. breast cancer diagnostics market projected to reach approximately $4.5 billion by 2033.
• Employs a strategic business-to-business-to-consumer (B2B2C) commercialization model with partnerships through CLIA-certified laboratories.
• Has a pipeline of additional assays in development for lung, ovarian, and pancreatic cancers, and potential longer-term applications in other inflammation-driven conditions like cardiovascular and neurodegenerative diseases.

Negatives

• Reported a net loss of $2,236,433 for the year ended December 31, 2025, following a $3,016,884 net loss in 2024.
• Accumulated deficit reached $9,495,799 as of December 31, 2025.
• Working capital deficit increased significantly to $4,397,372 as of December 31, 2025, from $2,378,145 at December 31, 2024.
• Independent auditors raised "substantial doubt about the Company's ability to continue as a going concern" due to recurring losses and negative cash flows.
• Generated $0 in revenue from operations for the year ended December 31, 2025, and only $217 in 2024.
• Commercialization plan is explicitly dependent on securing additional funding, which is not assured.
• Internal controls over financial reporting were concluded to be "not effective" as of December 31, 2025.
• The company's tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA).
• Principal shareholders hold approximately 77% of voting power, which could lead to actions not in the best interests of other shareholders.
• Common stock is considered a "penny stock," subjecting it to marketability restrictions and potential volatility.

Risks

• The company is an early-stage genomics technology company without any products or services currently available for sale and may not be able to successfully develop or bring products to market.
• Operations have a limited history, making it difficult to evaluate prospects and future performance, and the company expects to sustain losses for the next twelve months.
• Internal controls may be inadequate, potentially causing unreliable financial reporting and misinformation.
• Principal shareholders have significant voting power (approximately 77%), which may allow them to control corporate actions in ways that conflict with other shareholders' interests.
• The independent auditors' report indicates substantial doubt about the company's ability to continue as a going concern, which may impair its ability to raise capital.
• The company has incurred significant losses in prior periods and expects to require substantial additional capital to fund operations, research, development, clinical studies, and commercialization efforts.
• Failure to raise additional financing in a timely manner or on acceptable terms could force the company to scale back, delay, or cease operations, or result in significant dilution to shareholders.
• The company faces challenges in developing distinct sales and marketing channels for its complex B2C and B2B product candidates.
• Reliance on third-party logistics providers and contract manufacturing organizations introduces risks related to quality control, supply chain disruptions, and contractual performance.
• Revenue and results of operations may vary significantly and fail to meet expectations due to market conditions, competition, and operational factors.
• Failure to effectively manage growth, including hiring and retaining key personnel, could harm the business.
• Significant disruptions of information technology systems or security breaches could adversely affect operations, data privacy, and lead to financial, legal, and reputational harm.
• Compliance with evolving privacy laws and standards (e.g., HIPAA, HITECH, GDPR, CCPA, CPRA) is costly and complex, with potential for fines, sanctions, or litigation.
• The business plan is not based on independent market studies, relying on management's experience, judgment, and assumptions, which may prove incorrect.
• The Board of Directors may change company policies without stockholder approval.
• Limitations of director liability and indemnification provisions may discourage lawsuits against directors for breach of fiduciary duties.
• As an emerging growth company and smaller reporting company, the company intends to take advantage of reduced disclosure requirements, which could make its common stock less attractive to investors and financial comparisons more difficult.
• Successful commercialization depends on public acceptance of RNA-based products, and negative perceptions or increased regulation could adversely affect sales.
• The U.S. Food and Drug Administration (FDA) may begin actively regulating laboratory-developed tests (LDTs), requiring substantial costs and delays for premarket clearance or approval.
• The company faces intense competition from larger, more established, and better-capitalized companies in the medical testing products industry.
• Manufacturing processes for mRNA genomic technology are innovative and complex, potentially leading to difficulties with production, product releases, shelf life, and supply chain management.
• Materials and specialized equipment for diagnostic tests and RNA-based products may become difficult to obtain in required quality or quantity, or at projected prices.
• Marketing strategies for new products may not be successful, particularly if home testing kits are not covered by insurance.
• The company may become involved in litigation and government investigations, which can be expensive and distracting.
• Inability to obtain and maintain patent protection for technology and products, or challenges to existing patents, could reduce value and competitive advantage.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights.
• Inability to protect the confidentiality of trade secrets could harm the business and competitive position.
• Uncertainties in registering and enforcing trademarks.
• The company is authorized to issue Convertible Preferred Stock without stockholder approval, which could adversely impact the rights of common stock holders.
• Outstanding indebtedness pursuant to Convertible Notes, with default potentially affecting financial condition and ability to operate.
• Future issuances of debt or equity securities could negatively affect the market price of common stock and dilute existing stockholders.
• The company does not intend to pay dividends on its common stock, meaning returns depend solely on stock price appreciation.
• Management has broad discretion in the use of funds, and ineffective use could harm the business.
• The common stock is considered a "penny stock," subject to restrictions on marketability and potential volatility.
• Techniques employed by short sellers may drive down the market price of the common stock.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, the market price and trading volume could decline.
• The company may be subject to securities litigation, which is expensive and could divert management's attention.
• The costs of being a public company could result in the company being unable to continue as a going concern.

Future Outlook

The company anticipates trial-launching its first product candidate, the Revealia Breast test, in the second quarter of 2026. Its commercialization plan is contingent on securing additional funding for clinical validation studies, expanding laboratory infrastructure, and building distribution capabilities. The company plans to expand validation through further observational analyses and studies enrolling approximately 600 patients across various cancers, expected to begin within six months. Longer-term, it intends to evaluate applications for inflammation-driven conditions beyond oncology and develop a proprietary mRNA Inflammatory Index database for pharmaceutical R&D. The company expects to expand its workforce as it moves towards commercialization and further assay development.

Management Comments

• "We believe we are the first to employ a non-invasive cheek swab to collect mRNA samples in quantities sufficient for analysis."
• "Our approach seeks to enable earlier detection of inflammation-driven disease and to support personalized treatment decisions."
• "We believe our technology may provide an early warning system for conditions that today are often detected only after substantial damage has occurred."
• "Our commercialization plan is dependent on securing funding to fund additional clinical validation studies, expand laboratory infrastructure, and build distribution capabilities."
• "We believe this distinction positions us in a differentiated category within the broader genetic testing market."
• "We believe that through the launch of our more convenient, non-invasive Revealia Breast test, we can help to close these gaps [in early detection]."
• "We believe this transaction [Abbott acquiring Exact Sciences] underscores the strategic value that large healthcare companies place on scalable, early detection diagnostic platforms with established payer relationships."
• "We believe coverage and reimbursement will be a key driver of long-term adoption."
• "We are not undertaking to publicly update or revise any forward-looking statement if we obtain new information or upon the occurrence of future events or otherwise."
• "We intend to seek interim short-term financing to assure full legal compliance with our Securities and Exchange Commission (SEC) filings, and to bring on the necessary personnel to begin our future development activities."

Industry Context

StockSavvy.ai notes that Ludwig Enterprises is positioning itself in the rapidly growing genomic diagnostics market, specifically targeting inflammation-related chronic diseases and cancers. The company's focus on mRNA-based, non-invasive cheek swab tests differentiates it from competitors like Natera (circulating tumor DNA), Guardant Health (blood-based colorectal cancer screening), Exai Bio (oncRNA + AI), Exact Sciences (stool-based DNA, tissue-based genomic tests), GRAIL (multi-cancer cfDNA), Freenome (multiomics blood tests), DELFI Diagnostics (cfDNA fragmentomics), and Avantect (cfDNA for pancreatic cancer). The market is characterized by a shift towards proactive, preventive, and personalized healthcare, with a significant unmet need for earlier disease detection tools, as evidenced by the projected growth of the U.S. breast cancer diagnostics market to $4.5 billion by 2033. The acquisition of Exact Sciences by Abbott for $21 billion highlights the strategic value placed on scalable early detection platforms, suggesting a potential for significant industry consolidation and investment in this space.

Comparison to Industry Standards

• The Revealia Breast test's preliminary clinical performance (92% sensitivity, 54% specificity, 86% NPV, AUC of 76%) compares favorably to published benchmarks for mammography, which often has lower sensitivity in certain populations (e.g., dense breasts).
• The non-invasive cheek swab collection method offers a significant convenience advantage over blood-based tests (e.g., Natera's Signatera, Guardant Health's Shield, GRAIL's Galleri, Freenome's multiomics tests, DELFI's FirstLook Lung, Avantect's pancreatic cancer assay) and stool-based tests (Exact Sciences' Cologuard Plus), which require clinical blood draws or less patient-friendly sample collection.
• Unlike DNA-based assays (e.g., Natera, Guardant, GRAIL) that identify inherited variants or tumor-derived DNA, Ludwig's mRNA-based approach is designed to assess dynamic gene expression, aiming to capture earlier biological signals of active disease processes.
• The company's B2B2C commercialization strategy aims to adapt elements of Cologuard's successful model, focusing on clinically mediated access and payer alignment, which is a proven pathway for diagnostic market penetration.
• For ovarian cancer, where no approved routine population-level screening test currently exists and tools like CA-125 testing and transvaginal ultrasound lack sufficient early detection efficacy, Ludwig's developing Revealia ovarian assay aims to fill a critical unmet need with its molecular signal detection.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings.

Related Party Transactions

• Issued promissory notes to Thornhill Advisory Group (beneficially owned by CFO Scott J. Silverman) in November 2025 for $9,018 (1% interest) and in December 2025 for $8,865 (8% interest); both notes were repaid in February 2026.
• Issued a promissory note to former CEO Charles Todd, Jr. on March 10, 2025, for $36,912 (8% interest), which was extended to May 31, 2026.
• Issued a promissory note to Interim CEO Jose Antonio Reyes on December 17, 2024, for $5,000 (8% interest), which was redeemed in May 2025 for $5,000 principal and $165 accrued interest.
• Entered into a royalty agreement with Dr. Marvin Hausman (Chief Science Officer) and Nova Mentis Life Science Corp., requiring payment of 5% of gross sales from commercialization of an acquired patent, payable 2.5% each, for a period of ten years after Hausman receives $245,712 in consulting consideration.
• Accrued fees payable to Thornhill Advisory Group (Scott J. Silverman) were $98,058 as of December 31, 2025, and $56,375 as of December 31, 2024.
• Accrued fees payable to Jose Antonio Reyes were $161,250 as of December 31, 2025, and $56,250 as of December 31, 2024.
• Accrued fees payable to Dr. Marvin Hausman were $205,000 as of December 31, 2025, and $100,000 as of December 31, 2024.
• Former CEO Charles Todd paid operating expenses of $15,247 on behalf of the company in 2025.
• On March 12, 2026, the company entered into a settlement agreement with former CEO Charles Todd, Jr. to pay $275,147 (for accrued salary and his outstanding note payable of $36,912 plus 8% interest) within 7 days of an uplisting and fundraise, and to immediately issue 4,597,090 restricted shares of common stock.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity-based capital raises and the conversion of preferred stock. Existing common stock holders are exposed to substantial risk of loss due to the company's going concern warning, recurring losses, and penny stock status. Principal shareholders maintain significant voting power, which could influence corporate decisions.
• **Employees:** Future success is highly dependent on the company's ability to attract, develop, and retain highly qualified personnel. The departure of key executive officers could materially adversely affect business operations. Compensation for key executives is partially accrued, indicating potential payment delays.
• **Customers/Patients:** Potential for earlier disease detection and personalized treatment through the non-invasive mRNA tests. However, commercialization is uncertain and dependent on funding, and tests are not FDA approved. The initial consumer-paid model may limit access for some patients.
• **Creditors:** The company has significant outstanding indebtedness (convertible notes, promissory notes) and a substantial working capital deficit, raising concerns about its ability to meet financial obligations as they become due. Some notes have been extended due to inability to repay.
• **Suppliers/Partners:** The company's reliance on third-party logistics providers and laboratory partners introduces risks related to quality control, supply chain disruptions, and contractual performance, which could impact product development and commercialization.

Next Steps

• Trial launch of the Revealia Breast test in the second quarter of 2026.
• Continued metadata analysis across the breast cancer cohort.
• Initiation of additional observational analyses and planned studies enrolling approximately 600 patients across breast, lung, ovarian, and pancreatic cancers within six months.
• Securing additional funding to support clinical validation studies, expand laboratory infrastructure, and build distribution capabilities.
• Pursuing coverage and reimbursement from captive insurers, commercial insurers, and public health programs.
• Obtaining CLIA certification and CAP accreditation for partner laboratories.
• Building awareness through digital marketing, educational outreach, and physician engagement.
• Evaluating other inflammation-driven conditions (cardiovascular, autoimmune, neurodegenerative diseases) as longer-term opportunities for platform application.
• Developing a proprietary mRNA Inflammatory Index database for potential pharmaceutical R&D and drug development partnerships.
• Expanding the workforce to support commercialization and development of additional assays.
• Implementing a reverse stock split (between 1-for-50 and 1-for-250) and changing the company name to Revealia Diagnostics, Inc., as approved by shareholders and the board.

Key Dates

Recommendation

Ludwig Enterprises presents an extremely high-risk investment profile. The company has reported zero revenue from operations in 2025, significant and increasing net losses, a substantial accumulated deficit, and a severe working capital deficit. The independent auditors have explicitly raised "substantial doubt about the Company's ability to continue as a going concern," which is a critical red flag for investors. While the company is developing innovative genomic diagnostic technology with promising preliminary clinical results for its Revealia Breast test, its commercialization is entirely dependent on securing additional, uncertain funding. The stock's "penny stock" status, ineffective internal controls, and the potential for significant shareholder dilution from future capital raises further compound the risks. A seasoned investor would view the current financial instability and operational uncertainties as overwhelming, making a "Strong Sell" recommendation appropriate until the company demonstrates a clear path to sustainable revenue, profitability, and resolves its going concern issues.

Keywords

Genomic diagnostics, mRNA testing, Cancer screening, Revealia Breast test, Inflammation-related diseases, Early detection, Oncology, Biotechnology, Laboratory Developed Test (LDT), CLIA-certified, CAP-accredited, Machine learning, Patent, SEC filing, 10-K, Ludwig Enterprises, Revealia Diagnostics, Going concern, Reverse stock split